CMPX

CMPX

Compass Therapeutics Inc.

Rev โ€”top 1%5Y
Hold

Compass Therapeutics develops antibody-based therapeutics targeting cancer, focusing on angiogenesis and immune response. Its pipeline includes bispecific antibodies and monoclonal antibodies aimed at enhancing anti-tumor activity and overcoming immune evasion.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 30 years ago โ†’$665today

Score Overview

1 Year
Scoreโ€”
Net Growth-10.46%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth10.63%
Net Trend20%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev Trend20%
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth10.63%
Net Trend20%
Net Income Consistency
Rev Growthโ€”
Rev Trend20%
Revenue Consistency

See the full market ranking โ†’

Compass Therapeutics Inc. fundamental performance

Across Compass Therapeutics Inc.'s full reported history, from 2021 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 82M to -$ 66M. Revenue increased in 20% of the years measured; net income in 20%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 2.37โ€”
1 Year2025-08-12
$ 3.17-25.24%
5 Years2021-08-11
$ 4.08-41.91%
10 Years2006-02-24
$ 8.36-71.65%
20 Years2006-02-24
$ 8.36-71.65%
30 Years1996-08-12
$ 3.56-33.47%
All Time2021-04-05
$ 8.50-72.12%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 73M$ 179M
2025$ 0.00-$ 66M$ 208M
2024$ 850K-$ 49M$ 126M
2023$ 0.00-$ 42M$ 152M
2022$ 0.00-$ 39M$ 186M
IPO2021$ 0.00-$ 82M$ 144M

Explore beyond CMPX

You're looking at Compass Therapeutics Inc.. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies